![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 55, Issue 5, 921-928, May 1999
Department of Cancer Chemotherapy, Institute for Cancer Research,
Faculty of Medicine, Kagoshima University, Kagoshima, Japan
(Z-S.C., T.F., T.S., S.A.);
Experimental Technology Research Center,
Tokyo Research and Development Center, Daiichi Pharmaceutical
Co., Ltd., Tokyo, Japan (K.O.);
Laboratory of Biochemistry, Division of
Applied Life Sciences, Graduate School of Agriculture, Kyoto
University, Kyoto, Japan (K.U.); and
Research Planning Department,
Pharmaceutical Division, Nissan Chemical Industries, Ltd., Tokyo, Japan
(K.S.)
Non-P-glycoprotein-mediated multidrug-resistant C-A120 cells that
overexpressed multidrug resistance protein (MRP) were 10.8- and
29.6-fold more resistant to
7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) and SN-38, respectively, than parental KB-3-1 cells. To
see whether MRP is involved in CPT-11 and SN-38 resistance, MRP cDNA was transfected into KB-3-1 cells. The
transfectant, KB/MRP, which overexpressed MRP, was resistant to both
CPT-11 and SN-38.
2-[4-Diphenylmethyl)-1-piperazinyl]ethyl-5-(trans-4,6-dimethyl-1,3,2-dioxaphosphorinan-2-yl)-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate P-oxide (PAK-104P) and MK571, which reversed drug resistance in MRP overexpressing multidrug-resistant cells, significantly increased the sensitivity of C-A120 and KB/MRP cells, but not of KB-3-1 cells, to
CPT-11 and SN-38. The accumulation of both CPT-11 and SN-38 in C-A120
and KB/MRP cells was lower than that in KB-3-1 cells. The treatment
with 10 µM PAK-104P increased the accumulation of CPT-11 and
SN-38 in C-A120 and KB/MRP cells to a level similar to that found in
KB-3-1 cells. The ATP-dependent efflux of CPT-11 and SN-38 from C-A120
and KB/MRP cells was inhibited by PAK-104P. DNA topoisomerase I
expression, activity, and sensitivity to SN-38 were similar in the
three cell lines. Furthermore, the conversion of CPT-11 to SN-38 in
KB-3-1 and C-A120 cell lines was similar. These findings suggest that
MRP transports CPT-11 and SN-38 and is involved in resistance to CPT-11
and SN-38 and that PAK-104P reverses the resistance to CPT-11 and SN-38
in tumors that overexpress MRP.
This article has been cited by other articles:
|
|
 |
|
  Z. Liao, R. W. Robey, J. Guirouilh-Barbat, K. K. W. To, O. Polgar, S. E. Bates, and Y. Pommier Reduced Expression of DNA Topoisomerase I in SF295 Human Glioblastoma Cells Selected for Resistance to Homocamptothecin and Diflomotecan Mol. Pharmacol., February 1, 2008; 73(2): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Kroetz Role for Drug Transporters Beyond Tumor Resistance: Hepatic Functional Imaging and Genotyping of Multidrug Resistance Transporters for the Prediction of Irinotecan Toxicity J. Clin. Oncol., September 10, 2006; 24(26): 4225 - 4227. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Arakawa, H. Suzuki, S. Saito, and H. Yamada Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells. Mol. Cancer Ther., March 1, 2006; 5(3): 502 - 508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Norris, J. Smith, K. Tanabe, P. Tobin, C. Flemming, G. L. Scheffer, P. Wielinga, S. L. Cohn, W. B. London, G. M. Marshall, et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro Mol. Cancer Ther., April 1, 2005; 4(4): 547 - 553. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Cunningham, Y. Humblet, S. Siena, D. Khayat, H. Bleiberg, A. Santoro, D. Bets, M. Mueser, A. Harstrick, C. Verslype, et al. Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer N. Engl. J. Med., July 22, 2004; 351(4): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Hopper-Borge, Z.-S. Chen, I. Shchaveleva, M. G. Belinsky, and G. D. Kruh Analysis of the Drug Resistance Profile of Multidrug Resistance Protein 7 (ABCC10): Resistance to Docetaxel Cancer Res., July 15, 2004; 64(14): 4927 - 4930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. J. Mathijssen, S. Marsh, M. O. Karlsson, R. Xie, S. D. Baker, J. Verweij, A. Sparreboom, and H. L. McLeod Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics Clin. Cancer Res., August 1, 2003; 9(9): 3246 - 3253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rajendra, M. K. Gounder, A. Saleem, J. H. M. Schellens, D. D. Ross, S. E. Bates, P. Sinko, and E. H. Rubin Differential Effects of the Breast Cancer Resistance Protein on the Cellular Accumulation and Cytotoxicity of 9-Aminocamptothecin and 9-Nitrocamptothecin Cancer Res., June 15, 2003; 63(12): 3228 - 3233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Leslie, R. J. Bowers, R. G. Deeley, and S. P. C. Cole Structural Requirements for Functional Interaction of Glutathione Tripeptide Analogs with the Human Multidrug Resistance Protein 1 (MRP1) J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 643 - 653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu and M. A. Villalona-Calero Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity Ann. Onc., December 1, 2002; 13(12): 1841 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Turner, S. Gururangan, J. Eastwood, K. Bottom, M. Watral, R. Beason, R. E. McLendon, A. H. Friedman, S. Tourt-Uhlig, L. L. Miller, et al. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: The Duke experience Neuro-oncol, April 1, 2002; 4(2): 102 - 108. [Abstract] [PDF]
|
|
|
|
|
|
R. Garcia-Carbonero and J. G. Supko Current Perspectives on the Clinical Experience, Pharmacology, and Continued Development of the Camptothecins Clin. Cancer Res., March 1, 2002; 8(3): 641 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. GOTO, Y. IHARA, Y. URATA, S. IZUMI, K. ABE, T. KOJI, and T. KONDO Doxorubicin-induced DNA intercalation and scavenging by nuclear glutathione S-transferase {pi} FASEB J, December 1, 2001; 15(14): 2702 - 2714. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Bomgaars, S. L. Berg, and S. M. Blaney The Development of Camptothecin Analogs in Childhood Cancers Oncologist, December 1, 2001; 6(6): 506 - 516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Gamcsik, M. S. Kasibhatla, D. J. Adams, J. L. Flowers, O. M. Colvin, G. Manikumar, M. Wani, M. E. Wall, G. Kohlhagen, and Y. Pommier Dual Role of Glutathione in Modulating Camptothecin Activity: Depletion Potentiates Activity, but Conjugation Enhances the Stability of the Topoisomerase I-DNA Cleavage Complex Mol. Cancer Ther., November 1, 2001; 1(1): 11 - 20. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Perego, M. De Cesare, P. De Isabella, N. Carenini, G. Beggiolin, G. Pezzoni, M. Palumbo, L. Tartaglia, G. Pratesi, C. Pisano, et al. A Novel 7-modified Camptothecin Analog Overcomes Breast Cancer Resistance Protein-associated Resistance in a Mitoxantrone-selected Colon Carcinoma Cell Line Cancer Res., August 1, 2001; 61(16): 6034 - 6037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Okumura, Z.-S. Chen, M. Sakou, T. Sumizawa, T. Furukawa, M. Komatsu, R. Ikeda, H. Suzuki, K. Hirota, T. Aikou, et al. Reversal of P-Glycoprotein and Multidrug-Resistance Protein-Mediated Drug Resistance in KB Cells by 5-O-Benzoylated Taxinine K Mol. Pharmacol., April 13, 2001; 58(6): 1563 - 1569. [Abstract] [Full Text]
|
|
|
|
|
|
A. K. Larsen, C. Gilbert, G. Chyzak, S. Y. Plisov, I. Naguibneva, O. Lavergne, L. Lesueur-Ginot, and D. C. H. Bigg Unusual Potency of BN 80915, a Novel Fluorinated E-ring Modified Camptothecin, toward Human Colon Carcinoma Cells Cancer Res., April 1, 2001; 61(7): 2961 - 2967. [Abstract] [Full Text]
|
|
|
|
|
|
J. D. Allen, R. F. Brinkhuis, L. v. Deemter, J. Wijnholds, and A. H. Schinkel Extensive Contribution of the Multidrug Transporters P-Glycoprotein and Mrp1 to Basal Drug Resistance Cancer Res., October 1, 2000; 60(20): 5761 - 5766. [Abstract] [Full Text]
|
|
|
|
|
|
H. Zeng, L. J. Bain, M. G. Belinsky, and G. D. Kruh Expression of Multidrug Resistance Protein-3 (Multispecific Organic Anion Transporter-D) in Human Embryonic Kidney 293 Cells Confers Resistance to Anticancer Agents Cancer Res., December 1, 1999; 59(23): 5964 - 5967. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Q. Ren, T. Furukawa, S. Aoki, T. Nakajima, T. Sumizawa, M. Haraguchi, Z.-S. Chen, M. Kobayashi, and S.-i. Akiyama Glutathione-dependent Binding of a Photoaffinity Analog of Agosterol A to the C-terminal Half of Human Multidrug Resistance Protein J. Biol. Chem., June 15, 2001; 276(25): 23197 - 23206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K.-i. Ito, C. J. Oleschuk, C. Westlake, M. Z. Vasa, R. G. Deeley, and S. P. C. Cole Mutation of Trp1254 in the Multispecific Organic Anion Transporter, Multidrug Resistance Protein 2 (MRP2) (ABCC2), Alters Substrate Specificity and Results in Loss of Methotrexate Transport Activity J. Biol. Chem., October 5, 2001; 276(41): 38108 - 38114. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
